ParkinsonFranceV1, Main, Curation, bibRecord, 003132

Limitations of current Parkinson's disease therapy

Identifieur interne : 003132 ( Main/Curation ); précédent : 003131; suivant : 003133

Limitations of current Parkinson's disease therapy

Auteurs : Olivier Rascol [France] ; Pierre Payoux [France] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France, Portugal] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France]

Source :

Annals of Neurology [ 0364-5134 ] ; 2003.

RBID : ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E

Descripteurs français

Pascal (Inist)
- Agoniste, Amine oxidase (flavin-containing), Antiparkinsonien, Catechol O-methyltransferase, Chimiothérapie, Chirurgie, Homme, IMAO B, Indication, Inhibiteur enzyme, Lévodopa, Parkinson maladie, Récepteur dopaminergique, Stimulant dopaminergique, Sélégiline, Toxicité, Traitement.
Wicri :
- topic : Chirurgie, Homme.

English descriptors

KwdEn :
- Agonist, Amine oxidase (flavin-containing), Antiparkinson Agents (adverse effects), Antiparkinson Agents (classification), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Catechol O-methyltransferase, Chemotherapy, Cognition Disorders (chemically induced), Dopamine agonist, Dopamine receptor, Drug Resistance, Dysarthria (chemically induced), Dyskinesia, Drug-Induced (etiology), Electric Stimulation Therapy (methods), Enzyme inhibitor, Globus Pallidus (physiology), Globus Pallidus (surgery), Human, Humans, Indication, Levodopa, MAO B inhibitor, Neurosurgical Procedures, Parkinson Disease (drug therapy), Parkinson Disease (surgery), Parkinson Disease (therapy), Parkinson disease, Psychoses, Substance-Induced (etiology), Quality of Life, Selegiline, Subthalamic Nucleus (physiology), Subthalamic Nucleus (surgery), Surgery, Toxicity, Treatment.
MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , classification : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- chemically induced : Cognition Disorders, Dysarthria.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced, Psychoses, Substance-Induced.
- methods : Electric Stimulation Therapy.
- physiology : Globus Pallidus, Subthalamic Nucleus.
- surgery : Globus Pallidus, Parkinson Disease, Subthalamic Nucleus.
- therapy : Parkinson Disease.
- Drug Resistance, Humans, Neurosurgical Procedures, Quality of Life.

Abstract

Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15

Url:

https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/pdf

DOI: 10.1002/ana.10513

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001074
to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001072
to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000C87
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001131
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001090
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001090
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000316
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000316
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000316
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003606
to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F40
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000494
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000D70
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003733

Links to Exploration step

ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Limitations of current Parkinson's disease therapy</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name>
</author>
<author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name>
</author>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
</author>
<author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
</author>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/ana.10513</idno>
<idno type="url">https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001074</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001074</idno>
<idno type="wicri:Area/Istex/Curation">001072</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C87</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C87</idno>
<idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12666094</idno>
<idno type="wicri:Area/PubMed/Corpus">001131</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001131</idno>
<idno type="wicri:Area/PubMed/Curation">001090</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001090</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001090</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001090</idno>
<idno type="wicri:Area/Ncbi/Merge">000316</idno>
<idno type="wicri:Area/Ncbi/Curation">000316</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000316</idno>
<idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno>
<idno type="wicri:Area/Main/Merge">003606</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0329429</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F40</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000494</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D70</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D70</idno>
<idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno>
<idno type="wicri:Area/Main/Merge">003733</idno>
<idno type="wicri:Area/Main/Curation">003132</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Limitations of current Parkinson's disease therapy</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Nuclear Medicine, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Department of Neurology, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Neurology</title>
<title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title>
<title level="j" type="abbrev">Ann Neurol.</title>
<idno type="ISSN">0364-5134</idno>
<idno type="eISSN">1531-8249</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2003">2003</date>
<biblScope unit="volume">53</biblScope>
<biblScope unit="issue">S3</biblScope>
<biblScope unit="supplement">3</biblScope>
<biblScope unit="page" from="S3">S3</biblScope>
<biblScope unit="page" to="S15">S15</biblScope>
</imprint>
<idno type="ISSN">0364-5134</idno>
</series>
<idno type="istex">8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno>
<idno type="DOI">10.1002/ana.10513</idno>
<idno type="ArticleID">ANA10513</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (classification)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Cognition Disorders (chemically induced)</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Drug Resistance</term>
<term>Dysarthria (chemically induced)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Electric Stimulation Therapy (methods)</term>
<term>Enzyme inhibitor</term>
<term>Globus Pallidus (physiology)</term>
<term>Globus Pallidus (surgery)</term>
<term>Human</term>
<term>Humans</term>
<term>Indication</term>
<term>Levodopa</term>
<term>MAO B inhibitor</term>
<term>Neurosurgical Procedures</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (surgery)</term>
<term>Parkinson Disease (therapy)</term>
<term>Parkinson disease</term>
<term>Psychoses, Substance-Induced (etiology)</term>
<term>Quality of Life</term>
<term>Selegiline</term>
<term>Subthalamic Nucleus (physiology)</term>
<term>Subthalamic Nucleus (surgery)</term>
<term>Surgery</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cognition Disorders</term>
<term>Dysarthria</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Electric Stimulation Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Globus Pallidus</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term>
<term>Parkinson Disease</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Resistance</term>
<term>Humans</term>
<term>Neurosurgical Procedures</term>
<term>Quality of Life</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Antiparkinsonien</term>
<term>Catechol O-methyltransferase</term>
<term>Chimiothérapie</term>
<term>Chirurgie</term>
<term>Homme</term>
<term>IMAO B</term>
<term>Indication</term>
<term>Inhibiteur enzyme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Récepteur dopaminergique</term>
<term>Stimulant dopaminergique</term>
<term>Sélégiline</term>
<term>Toxicité</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Chirurgie</term>
<term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15</div>
</front>
</TEI>
<double idat="0364-5134:2003:Rascol O:limitations:of:current"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Limitations of current Parkinson's disease therapy. Discussion</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Nuclear Medicine, Toulouse, University Hospital</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
<wicri:noRegion>Department of Nuclear Medicine, Toulouse, University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Nuclear Medicine, Toulouse, University Hospital</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
<wicri:noRegion>Department of Nuclear Medicine, Toulouse, University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
<wicri:noRegion>Department of Neurology</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Nuclear Medicine, Toulouse, University Hospital</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
<wicri:noRegion>Department of Nuclear Medicine, Toulouse, University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0329429</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0329429 INIST</idno>
<idno type="RBID">Pascal:03-0329429</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F40</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000494</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D70</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D70</idno>
<idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno>
<idno type="wicri:Area/Main/Merge">003733</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Limitations of current Parkinson's disease therapy. Discussion</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Nuclear Medicine, Toulouse, University Hospital</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
<wicri:noRegion>Department of Nuclear Medicine, Toulouse, University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Nuclear Medicine, Toulouse, University Hospital</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
<wicri:noRegion>Department of Nuclear Medicine, Toulouse, University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
<wicri:noRegion>Department of Neurology</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Nuclear Medicine, Toulouse, University Hospital</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
<wicri:noRegion>Department of Nuclear Medicine, Toulouse, University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</s1>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>University Hospital France</wicri:noRegion>
<wicri:noRegion>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Antiparkinson agent</term>
<term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Enzyme inhibitor</term>
<term>Human</term>
<term>Indication</term>
<term>Levodopa</term>
<term>MAO B inhibitor</term>
<term>Parkinson disease</term>
<term>Selegiline</term>
<term>Surgery</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Stimulant dopaminergique</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Catechol O-methyltransferase</term>
<term>Sélégiline</term>
<term>IMAO B</term>
<term>Inhibiteur enzyme</term>
<term>Chirurgie</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Traitement</term>
<term>Indication</term>
<term>Toxicité</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Chirurgie</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the "honeymoon" period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from "dopa-resistant" motor symptoms (speech impairment, abnormal posture, gait and balance problems), "dopa-resistant" nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug-related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Limitations of current Parkinson's disease therapy</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name>
</author>
<author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name>
</author>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
</author>
<author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
</author>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/ana.10513</idno>
<idno type="url">https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001074</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001074</idno>
<idno type="wicri:Area/Istex/Curation">001072</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C87</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C87</idno>
<idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12666094</idno>
<idno type="wicri:Area/PubMed/Corpus">001131</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001131</idno>
<idno type="wicri:Area/PubMed/Curation">001090</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001090</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001090</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001090</idno>
<idno type="wicri:Area/Ncbi/Merge">000316</idno>
<idno type="wicri:Area/Ncbi/Curation">000316</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000316</idno>
<idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno>
<idno type="wicri:Area/Main/Merge">003606</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Limitations of current Parkinson's disease therapy</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Nuclear Medicine, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Department of Neurology, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Neurology</title>
<title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title>
<title level="j" type="abbrev">Ann Neurol.</title>
<idno type="ISSN">0364-5134</idno>
<idno type="eISSN">1531-8249</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2003">2003</date>
<biblScope unit="volume">53</biblScope>
<biblScope unit="issue">S3</biblScope>
<biblScope unit="supplement">3</biblScope>
<biblScope unit="page" from="S3">S3</biblScope>
<biblScope unit="page" to="S15">S15</biblScope>
</imprint>
<idno type="ISSN">0364-5134</idno>
</series>
<idno type="istex">8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno>
<idno type="DOI">10.1002/ana.10513</idno>
<idno type="ArticleID">ANA10513</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (classification)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cognition Disorders (chemically induced)</term>
<term>Drug Resistance</term>
<term>Dysarthria (chemically induced)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Electric Stimulation Therapy (methods)</term>
<term>Globus Pallidus (physiology)</term>
<term>Globus Pallidus (surgery)</term>
<term>Humans</term>
<term>Neurosurgical Procedures</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (surgery)</term>
<term>Parkinson Disease (therapy)</term>
<term>Psychoses, Substance-Induced (etiology)</term>
<term>Quality of Life</term>
<term>Subthalamic Nucleus (physiology)</term>
<term>Subthalamic Nucleus (surgery)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cognition Disorders</term>
<term>Dysarthria</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Electric Stimulation Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Globus Pallidus</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term>
<term>Parkinson Disease</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Resistance</term>
<term>Humans</term>
<term>Neurosurgical Procedures</term>
<term>Quality of Life</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15</div>
</front>
</TEI>
</ISTEX>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003132 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003132 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E
   |texte=   Limitations of current Parkinson's disease therapy
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Limitations of current Parkinson's disease therapy

Limitations of current Parkinson's disease therapy

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri